B. Riley analyst Yuan Zhi lowered the firm’s price target on Actinium Pharmaceuticals to $16 from $20 and keeps a Buy rating on the shares. The analyst believes the subgroup analysis of the Phase III SIERRA trial indicate a high likelihood for approval. The firm cites the delayed commercial launch of Iomab-B to 2025 for the target drop.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ATNM:
